Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

Similar articles for PubMed (Select 21962618)

1.

Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials.

Velez JC, Nietert PJ.

Am J Kidney Dis. 2011 Dec;58(6):928-38. doi: 10.1053/j.ajkd.2011.07.017. Epub 2011 Sep 29.

2.

An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.

Sharma P, Kumar A, Shrama BC, Sarin SK.

Am J Gastroenterol. 2008 Jul;103(7):1689-97. doi: 10.1111/j.1572-0241.2008.01828.x. Epub 2008 Jun 28.

PMID:
18557715
3.

Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study.

Ghosh S, Choudhary NS, Sharma AK, Singh B, Kumar P, Agarwal R, Sharma N, Bhalla A, Chawla YK, Singh V.

Liver Int. 2013 Sep;33(8):1187-93. doi: 10.1111/liv.12179. Epub 2013 Apr 21.

PMID:
23601499
4.

Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome.

Uriz J, Ginès P, Cárdenas A, Sort P, Jiménez W, Salmerón JM, Bataller R, Mas A, Navasa M, Arroyo V, Rodés J.

J Hepatol. 2000 Jul;33(1):43-8.

PMID:
10905585
5.

Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome.

Saló J, Ginès A, Quer JC, Fernández-Esparrach G, Guevara M, Ginès P, Bataller R, Planas R, Jiménez W, Arroyo V, Rodés J.

J Hepatol. 1996 Dec;25(6):916-23.

PMID:
9007721
6.

Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics.

Boyer TD, Sanyal AJ, Garcia-Tsao G, Blei A, Carl D, Bexon AS, Teuber P; Terlipressin Study Group.

J Hepatol. 2011 Aug;55(2):315-21. doi: 10.1016/j.jhep.2010.11.020. Epub 2010 Dec 15.

7.

Targeting an early and substantial increase in mean arterial pressure is critical in the management of type 1 hepatorenal syndrome: a combined retrospective and pilot study.

Maddukuri G, Cai CX, Munigala S, Mohammadi F, Zhang Z.

Dig Dis Sci. 2014 Feb;59(2):471-81. doi: 10.1007/s10620-013-2899-z. Epub 2013 Oct 22.

PMID:
24146317
8.

Terlipressin for hepatorenal syndrome: A meta-analysis of randomized trials.

Fabrizi F, Dixit V, Messa P, Martin P.

Int J Artif Organs. 2009 Mar;32(3):133-40. Review.

PMID:
19440988
9.

Terlipressin in hepatorenal syndrome: Evidence for present indications.

Rajekar H, Chawla Y.

J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:109-14. doi: 10.1111/j.1440-1746.2010.06583.x. Review.

PMID:
21199521
10.

Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.

Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, Amodio P, Sticca A, Caregaro L, Maffei-Faccioli A, Gatta A.

Hepatology. 1999 Jun;29(6):1690-7.

PMID:
10347109
11.

Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial.

Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK.

J Gastroenterol Hepatol. 2003 Feb;18(2):152-6.

PMID:
12542598
12.

Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome.

Nazar A, Pereira GH, Guevara M, Martín-Llahi M, Pepin MN, Marinelli M, Solá E, Baccaro ME, Terra C, Arroyo V, Ginès P.

Hepatology. 2010 Jan;51(1):219-26. doi: 10.1002/hep.23283.

PMID:
19877168
13.

Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome.

Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA.

Dig Dis Sci. 2007 Mar;52(3):742-8.

PMID:
17235705
14.

Vasoconstrictor therapy for hepatorenal syndrome in liver cirrhosis.

Schmidt LE, Ring-Larsen H.

Curr Pharm Des. 2006;12(35):4637-47. Review.

PMID:
17168767
15.

Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion.

Guevara M, Ginès P, Fernández-Esparrach G, Sort P, Salmerón JM, Jiménez W, Arroyo V, Rodés J.

Hepatology. 1998 Jan;27(1):35-41.

PMID:
9425914
16.

Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study.

Halimi C, Bonnard P, Bernard B, Mathurin P, Mofredj A, di Martino V, Demontis R, Henry-Biabaud E, Fievet P, Opolon P, Poynard T, Cadranel JF.

Eur J Gastroenterol Hepatol. 2002 Feb;14(2):153-8.

PMID:
11981339
17.

Terlipressin for hepatorenal syndrome.

Gluud LL, Kjaer MS, Christensen E.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD005162. Review. Update in: Cochrane Database Syst Rev. 2012;9:CD005162.

PMID:
17054242
18.

Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials.

Sagi SV, Mittal S, Kasturi KS, Sood GK.

J Gastroenterol Hepatol. 2010 May;25(5):880-5. doi: 10.1111/j.1440-1746.2009.06132.x. Epub 2010 Jan 14. Review.

PMID:
20074149
19.

Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine.

Gülberg V, Bilzer M, Gerbes AL.

Hepatology. 1999 Oct;30(4):870-5.

PMID:
10498636
20.

Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: a case-control study.

Alessandria C, Debernardi-Venon W, Carello M, Ceretto S, Rizzetto M, Marzano A.

Dig Liver Dis. 2009 Apr;41(4):298-302. doi: 10.1016/j.dld.2008.09.014. Epub 2009 Jan 20.

PMID:
19158001
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk